🇺🇸 FDA
Pipeline program

AUY922

CAUY922A2109

Phase 2 small_molecule completed

Quick answer

AUY922 for Advanced HER2-positive Breast Cancer is a Phase 2 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Advanced HER2-positive Breast Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials